Verrica Pharma Rg

Verrica Pharma develops top-tier dermatology therapeutics. Its pipeline includes VP-102 (phase III for common warts), VP-315 (phase II oncolytic peptide for skin cancer) and VP-103 (cantharidin for plantar warts). Partnerships with Torii and Lytix expand U.S./Japan reach.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 71
HQ: West Chester

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
VRCA	Verrica Pharma Rg Cap: 0.1B	EQUITY	NGM	USD	US92511W1080	Active	📈